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rom Black and
hite to Shades of Gray
ace and Renin-Angiotensin
ystem Blockade*
dward P. Havranek, MD, FACC
enver, Colorado
n this issue of the Journal, Prisant et al. (1) present a
etrospective subgroup analysis of data from the VALIANT
Valsartan in Acute Myocardial Infarction Trial) study in
hich they show comparable outcomes for African-
merican and white patients with left ventricular dysfunc-
ion after a myocardial infarction regardless of the treatment
ssigned. The results of this analysis have important impli-
ations for the treatment of patients after a myocardial
nfarction, for the use of renin-angiotensin system (RAS)–
locking agents for African Americans with hypertension
nd heart failure, and for race-based treatment in general.
The parent study enrolled 14,703 patients in 24 countries;
articipants had had a myocardial infarction and had either
linically apparent heart failure or a reduced ejection frac-
ion. Subjects were randomized to receive valsartan, capto-
ril, or a combination of these. Overall, the 3 treatments
ad statistically indistinguishable effects on cardiovascular
vents and on all-cause mortality.
See page 1865
The current study is of the U.S. subset of 3,390 white and
40 African-American patients. In agreement with previous
omparisons by race of patients with heart failure, African-
merican patients were younger, more likely female, and
ore likely to have hypertension and diabetes. The inves-
igators compared African-American and white patients by
reatment group with regard to subsequent all-cause and
ardiovascular mortality, heart failure hospitalizations, myo-
ardial infarction, and stroke. Multivariable regression was
sed to adjust the outcomes for the racial differences in
aseline characteristics. For all end points studied, there
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Denver Health Medical Center, Denver, Colorado. Supported by
ational Heart, Lung, and Blood Institute grant U01 HL079160.ere no interactions between race and treatment assign-
ent.
Some may find these results surprising. There is a widely
eld view that African Americans with hypertension and
eart failure do not have a response to angiotensin-
onverting enzyme (ACE) inhibitors, which has some basis
n evidence from randomized trials. Exner et al. (2) analyzed
utcome data from the treatment and prevention arms of
he SOLVD (Studies on Left Ventricular Dysfunction) by
ace. Black subjects had slightly higher blood pressure at
aseline. Despite uniform treatment across race with ap-
roximately 15 mg/day enalapril, blood pressure decreased
ignificantly in the white subjects but did not change in the
lack subjects. In white subjects, enalapril treatment re-
uced the rate of heart failure hospitalizations, whereas in
lack subjects there was no effect. Similar results were
eported in an analysis of data from the ALLHAT (Anti-
ypertensive and Lipid-Lowering Treatment to Prevent
eart Attack) study by race (3). The relative risk for
ncident coronary heart disease, stroke, and heart failure was
ignificantly greater for black subjects treated with lisinopril
ompared with those treated with chlorthalidone; for non-
lack subjects the differences were not significant. As in the
OLVD study, blood pressure response to the ACE inhib-
tor was significantly less in black compared with nonblack
atients.
On closer examination, however, the racial differences in
utcomes in these studies are not quite as stark. In the
OLVD study, the effect of enalapril treatment on all-cause
ortality was the same in black and white subjects; treat-
ent was not associated with a reduction in mortality in
ither group. There are probably 2 reasons for the discor-
ance between the heart failure result and the mortality
esult. First, the rate of hospitalization for heart failure end
oint is much more likely to be affected by unmeasured
onfounding. Need for hospitalization is affected by factors
uch as insurance status and access to care, where African
mericans are at a disadvantage. Second, the sample size
eems to be too small to support the desired analyses. The
nding that enalapril did not reduce mortality in either
acial group contradicts clear and consistent findings that
CE inhibitors improve outcomes in patients with left
entricular dysfunction, and is almost certainly caused by
he numbers of observations being too small to detect small
ifferences in outcome.
In the ALLHAT study, a formal test of interaction
etween race and treatment for predicting heart failure was
ot significant. A negative finding on this more stringent
est suggests that racial differences in response to ACE
nhibition in heart failure prevention are quite small if
resent at all.
The best way to understand these findings is to view both
frican-American and white patients as having wide intra-
roup variation in response to ACE inhibition. Although
he mean response between the groups might be slightly
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May 13, 2008:1872–3 Editorial Commentifferent, the individual responses overlap substantially. This
iew is illustrated by the results of a study of perindopril
onotherapy for hypertension (4) in which blood pressure
ontrol was achieved in approximately 40% of African-
merican and 50% of white patients at 12 weeks. The
otion of substantial overlap in individual response is
onsistent with findings that show that African Americans
nd white Americans are not as different genetically as we
ight be conditioned to believe. In one recent study using
,154 single-nucleotide polymorphisms (5), the median
ercentage of European ancestry in a group of African
mericans was estimated to be approximately 25%, and was
ven 50% in a small subgroup. As our knowledge of the
uman genome expands, race is being seen increasingly as a
utable characteristic of human populations. A recent
nalysis of the HapMap database (6) suggests that the wide
ariability in human characteristics we use the term race to
escribe is a relatively recent development, occurring over
he past 40,000 years, with the rapid acceleration in human
volution resulting from explosive growth and spread of the
opulation.
In the case of RAS blockade, wide variation in individual
esponse likely results in a situation in which a majority of
hite and African-American individuals has a vigorous
esponse to RAS-blocking agents and a larger minority of
frican-American patients has a muted response. It seems
o be possible to circumvent this muted response easily.
hen upward titration of dose or addition of diuretics is
llowed in clinical trials, differences in response to RAS
lockade by race diminish. For example, in a study of
elmisartan in patients with hypertension in which concom-
tant use of diuretics was allowed (7), rates of hypertension
ontrol were similar for black and white patients despite
imilar telmisartan doses; black patients were more likely to
eceive concomitant diuretics.
The results of the current study should be interpreted and
pplied to the care of patients with left ventricular dysfunc-
ion after myocardial infarction with this background in
ind. The results do not suggest that angiotensin receptor
lockers offer advantages over ACE inhibitors for African
mericans; both drug classes should be viewed as effective
egardless of race. Therapy should be modified for individ-
al response regardless of race. Although African-American
atients in the VALIANT study were more likely to
evelop hyperkalemia and renal dysfunction, all patients
hould be monitored for these adverse effects, and doses of
iuretics and RAS-blocking agents should be modified if
hese adverse effects occur. How best to individualize
herapy to maximize efficacy is less clear. Prior data suggest
hat a slight decrement in blood pressure is associated with
etter outcomes. Although we do not know whether
frican-American and white patients in the VALIANT
tudy were treated with different doses, titrating doses
pward until an effect on blood pressure is seen may
mprove outcomes. African-American patients in theALIANT study were more likely at follow-up to be on
iuretics. Adding a diuretic when blood pressure remains
nchanged might improve effectiveness, but more data are
eeded before this approach can be recommended. Finally,
t should be recognized that the number of African-
merican patients studied was relatively small and that
ace–treatment interaction may have been significant if the
ample size had been larger.
There are disparities by race in the U.S. in the incidence
f potentially preventable cardiovascular disease, in the
valuation and treatment of cardiovascular disease, and in
he outcomes of cardiovascular disease. Possible sources for
hese disparities include the health consequences of inequal-
ty in education and employment, the effects of prejudice,
nd the inability to measure and act on differences in genetic
eterminants of disease and response to treatment. Seen in
his light, there are 2 problems with race-based therapy as a
trategy for addressing racial disparities. First, this strategy
gnores and diverts attention from social determinants of
isparities. Second, this strategy is an overly crude substitute
or measuring individual variability in genetic predisposition
o disease and response to therapy. The current study
llustrates this point well; known differences in response to
AS blockade by race were simply not great enough to
esult in a detectable difference in outcomes.
Differences in response to drug treatments by race are not
tark but subtle—not black and white but shades of gray.
ntil these subtle shadings can be measured more precisely
hrough individual genotyping, race-based therapy should
e approached with caution, if at all.
eprint requests and correspondence: Dr. Edward P. Havranek,
enver Health Medical Center #0960, 777 Bannock Street,
enver, Colorado 80204-4507. E-mail: ehavrane@dhha.org.
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